| Original language | English (US) |
|---|---|
| Pages (from-to) | e5-e8 |
| Journal | Biological psychiatry |
| Volume | 89 |
| Issue number | 3 |
| DOIs | |
| State | Published - Feb 1 2021 |
ASJC Scopus subject areas
- Biological Psychiatry
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Biological psychiatry, Vol. 89, No. 3, 01.02.2021, p. e5-e8.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Meta-analysis of the Glial Marker TSPO in Psychosis Revisited
T2 - Reconciling Inconclusive Findings of Patient–Control Differences
AU - Plavén-Sigray, Pontus
AU - Matheson, Granville J.
AU - Coughlin, Jennifer M.
AU - Hafizi, Sina
AU - Laurikainen, Heikki
AU - Ottoy, Julie
AU - De Picker, Livia
AU - Rusjan, Pablo
AU - Hietala, Jarmo
AU - Howes, Oliver D.
AU - Mizrahi, Romina
AU - Morrens, Manuel
AU - Pomper, Martin G.
AU - Cervenka, Simon
N1 - Funding Information: This work was supported by Swedish Research Council Grant No. 523-2014-3467 (to SC); the Swedish Society for Medical Research (to PP-S); the Lundbeck Foundation (to PP-S); Medical Research Council-UK Grant No. MC-A656-5QD30 (to ODH), Wellcome Trust Grant No. 094849/Z/10/Z (to ODH); the National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust (to ODH); King's College London (ODH); National Institute of Mental Health Grant Nos. EB024495 (to JMC), NS100847 (to JMC), and R01MH100043 (to RM); the One Mind - Gifford Foundation (to JMC); and Academy of Finland Grant Nos. 267982 (to JH) and 323036 (to HL). SC has received grant support from AstraZeneca as a coinvestigator and has served as a speaker for Otsuka. RM received travel support and speaking fees from Janssen for invited talks. LDP, MM, and JO received support from Janssen R&D to fund their study. RM has received travel support and speaker fees from Janssen and consulting fees from Otsuka-Lundbeck Canada. ODH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angelini, AstraZeneca, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Janssen, Lundbeck, Leyden-Delta, Mylan, Neurocrine, Otsuka, Sunovion, Rand, Recordati, and Roche. All other authors report no biomedical financial interests or potential conflicts of interest. Funding Information: This work was supported by Swedish Research Council Grant No. 523-2014-3467 (to SC); the Swedish Society for Medical Research (to PP-S); the Lundbeck Foundation (to PP-S); Medical Research Council -UK Grant No. MC-A656-5QD30 (to ODH), Wellcome Trust Grant No. 094849/Z/10/Z (to ODH); the National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust (to ODH); King’s College London (ODH); National Institute of Mental Health Grant Nos. EB024495 (to JMC), NS100847 (to JMC), and R01MH100043 (to RM); the One Mind - Gifford Foundation (to JMC); and Academy of Finland Grant Nos. 267982 (to JH) and 323036 (to HL).
PY - 2021/2/1
Y1 - 2021/2/1
UR - https://www.scopus.com/pages/publications/85089103229
UR - https://www.scopus.com/pages/publications/85089103229#tab=citedBy
U2 - 10.1016/j.biopsych.2020.05.028
DO - 10.1016/j.biopsych.2020.05.028
M3 - Letter
C2 - 32682565
AN - SCOPUS:85089103229
SN - 0006-3223
VL - 89
SP - e5-e8
JO - Biological psychiatry
JF - Biological psychiatry
IS - 3
ER -